Nikhil I. Khushalani, MD

Articles by Nikhil I. Khushalani, MD

Rationale for Combining a Modified IL-2 and Nivolumab in Melanoma

July 8th 2019

Nikhil I. Khushalani, MD, discusses the rationale for combining nivolumab with bempegaldesleukin for the treatment of patients with newly diagnosed, unresectable or metastatic melanoma in a randomized, open-label phase III trial.

Latest Updated Articles

Rationale for Combining a Modified IL-2 and Nivolumab in Melanoma
Published: July 8th 2019 | Updated:

Nikhil I. Khushalani, MD

Articles by Nikhil I. Khushalani, MD

Rationale for Combining a Modified IL-2 and Nivolumab in Melanoma

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors